Interpace Diagnostics Announces Participation at the DJCON18
October 24, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
Including Participation in the Panel on the Impact of AI and Bioinformatics in Healthcare PARSIPPANY, NJ, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics to Present at the 36th Annual Lab Institute 2018
October 22, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
Discussing Methods for Securing Coverage and Reimbursement for New Technologies PARSIPPANY, NJ, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today...
Interpace Diagnostics Presents Favorable New Data at the 88th Annual Meeting of the American Thyroid Association (ATA)
October 15, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
ThyGenX® and ThyraMIR® Data from Clinical Experience Study Shows Positive Results PARSIPPANY, NJ, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced that...
Interpace Diagnostics CEO Provides Corporate Update
October 10, 2018 08:30 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) is pleased to provide a corporate update to shareholders on current business activities from its Chief...
Interpace Diagnostics Enters into Agreement with Renowned Integrated Health System
October 04, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
Agreement with Piedmont Healthcare Covers Company’s Pancreatic Cancer Test PARSIPPANY, NJ, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) reported today that it has...
Interpace Diagnostics to Present New Data at the 88th Annual Meeting of the American Thyroid Association (ATA) on October 5th
October 01, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
ThyGenX® and ThyraMIR® Data from Clinical Experience Study to be Featured at ATA Product Expo PARSIPPANY, NJ, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...
Interpace Diagnostics Announces Reimbursement Expansion of ThyGeNEXT™
September 24, 2018 06:55 ET
|
Interpace Diagnostics Group, Inc.
State of Pennsylvania and New York Approve Commercialization of New Thyroid Cancer Test PARSIPPANY, NJ, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG), announced...
Interpace Diagnostics Supports Research Efforts of Pancreatic and Thyroid Cancer Patient Advocacy Groups
September 17, 2018 08:30 ET
|
Interpace Diagnostics Group, Inc.
Interpace Employees Participate in Local Events in Support of Lustgarten Foundation for Pancreatic Cancer Research, Thyroid, Head and Neck Cancer Foundation, and Pancreatic Cancer Action Network ...
INTERPACE DIAGNOSTICS ANNOUNCES PARTICIPATION AT THE 20TH ANNUAL GLOBAL INVESTMENT CONFERENCE SPONSORED BY H.C.WAINWRIGHT & CO.
August 27, 2018 08:30 ET
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Aug. 27, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...
Interpace Diagnostics to Present at the 10th Annual Next Generation Dx Summit 2018
August 20, 2018 16:30 ET
|
Interpace Diagnostics Group, Inc.
Discussing Methods for Securing Coverage and Reimbursement for Molecular Diagnostics PARSIPPANY, NJ, Aug. 20, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG)...